

## Research Article



## Antioxidant Potential of Ethanolic Extract of *Azadirachta excelsa* in Streptozotocin Induced Diabetic Rats

Nur Syimal'ain A. \*, Nooraain H., Nurdiana S., Noor Syaffinaz N.M.Z

School of Biology, Faculty of Applied Sciences, Universiti Teknologi MARA, Selangor, 40450. Shah Alam, Malaysia.

\*Corresponding author's E-mail: [syimalainazmi@gmail.com](mailto:syimalainazmi@gmail.com)

Received: 10-02-2017; Revised: 28-03-2017; Accepted: 14-04-2017.

### ABSTRACT

Free radicals and lipid peroxide, easily formed in the diabetic state, play an important part in the development of diabetic complications. Plant flavonoid has emerged as the popular therapeutic nature drugs effective against a broad range of diseases including diabetes. Antidiabetic properties of extracted *A. excelsa* have been proven in animal models. The present study designed to investigate the antioxidant activity of ethanolic extract of *A. excelsa*. The ethanolic extract of *A. excelsa* was administered orally (250 mg/kg, for 56 days) to streptozotocin-induced diabetic rats (STZ, 60 mg/kg b.wt). Antioxidant profile in diabetic rats treated with *A. excelsa* extract were assessed and compared to control (normal and diabetic rats). *A. excelsa* has higher potential to increase pancreatic antioxidant enzymes. Moreover, *A. excelsa* was also found to improve pancreatic cells replenishment through increase in pancreas weight as compared to diabetic control. Therefore, ethanolic extract of *A. excelsa* depicted a potential to ameliorate pancreas in diabetic rats better than the common drugs metformin. These results emphasize that *A. excelsa* could be a potential agent to attenuate pancreatic oxidative damage and advocate their therapeutic potential for treating DM.

**Keywords:** Diabetes Mellitus (DM); *A. excelsa*, quercetin, streptozotocin (STZ); antioxidant.

### INTRODUCTION

Diabetes mellitus (DM) is a silent pandemic with substantial morbidity and death rate, characterized by the presence of high blood glucose.<sup>1,2</sup> It is now considered an epidemic by considered previously as a disease of the affluent. The world prevalence of DM in 2010 was estimated at 6.4% or 285 million adults and it is expected this number will rise to 439 million adults in 2030.<sup>3</sup> Therefore, currently in 2011 it is involve about 347 million people worldwide, out of which 1.2 million have been diagnosed in Malaysia.<sup>4</sup> DM is a heterogeneous group of metabolic disorders characterized by hyperglycemia with impaired metabolism of carbohydrate, fat, and proteins as a result of defects in insulin secretion, insulin action, or both.<sup>5</sup>

There have been recent reports describing the potential of antioxidants to be developed as new therapies of diabetes. The leaves extract of *Azadirachta excelsa* which mainly contains azadirachtin has been proven to give promising effect as an antioxidant, antimicrobial, antimalarial, antiseptic agent and antidiabetic properties in animal models.<sup>6</sup> A study by Nurul'Izzati *et al.* showed *A. excelsa* leaves extract was also able to improve the liver catalase activity in rat models and help to improve plasma insulin secretion and decreasing the levels of fasting blood glucose and glycated haemoglobin (HbA1c).<sup>7,8</sup> It is expected that *A. excelsa* leaves extract might protect destruction of pancreas caused by diabetes. *A. excelsa* might help in regeneration of islet of Langerhans of pancreas and ameliorate the pancreas structure. Successful investigations, precise insights on the mechanism underlying the protective effect of *A. excelsa*

on diabetes may contribute to a finding of the new alternative therapy for diabetic patients.

### MATERIALS AND METHODS

#### Experimental Animal and Animal Management

Males Sprague Dawley rats with body weight range from 150 g to 200 g aged three months old were used in these studies. The animals were acclimatized for a week before being used for the experiments. The rats were kept in cages and maintained under standard room temperature between 24 °C to 27 °C.

Inductions of diabetes were conducted through intraperitoneal injection of 0.5 ml Streptozotocin (STZ) at 60 mg/kg bwt. STZ was freshly prepared in saline (9% sodium chloride) at 4°C. During the induction period, food and drink were provided *ad libitum*. In order to prevent from the drug-induced hypoglycemic shock, 5% glucose water was given to the rats orally by using oral gavage for two days soon after the injection of STZ.<sup>9</sup> After 1 week of induction, the rats were divided into four groups six rats each (Table 1).

**Table 1:** Treatment groups

	Group	Treatment	Dosage
I	Normal control (NC)	Saline	-
II	Diabetic control (DC)	Saline	-
III	Diabetic rats + Metformin (DMET)	Metformin	1000 mg/kg b. wt
IV	Diabetic rat + <i>A. excelsa</i> (DAE)	<i>A. excelsa</i> extract	250 mg/kg b. wt



Metformin and ethanolic extract of *A. excelsa* were dissolved in saline. Those treatments were given once daily for a duration of 8 weeks (56 days). General health and behavior of the animals were monitored during the entire study. At the end of the treatment, rats were fasted overnight and under slight anesthesia using diethyl ether, then the blood samples collected through cardiac puncture into plain sterilized centrifuge tubes. Serum were separated and stored at -80°C until analysis.

### Animals Use and Ethics in Research

The experimental protocols involving the use of rats as well as internationally accepted practices for the usage and maintenance of laboratory animals as contained in guidelines, reference number: UiTM CARE, 112/2015.

### Preparation of *Azadirachta excelsa* Extract

The leaves of *A. excelsa* plant (UKMB40314) were obtained from Forest Research Institute of Malaysia (FRIM), Kepong, Kuala Lumpur. The leaves of *A. excelsa* plant were cut, dried and ground to form powder. It was then soaked in 70% ethanol at 1:10 ratio (100 g powder: 1000 ml ethanol) for three days at room temperature (27°C). The ethanolic extract was collect in a conical flask. The mixture was filtered by using a vacuum pump, Buchner funnel and filter papers. The filtrate obtained was evaporated by using a rotary evaporator at 40°C.<sup>10</sup> A dark semi-solid paste obtained was stored at 4°C for further use.

### Preparation of Tissue Homogenates

Tissue samples were homogenized in 5–10 ml/g of homogenizing buffer (50 mM Tris-HCl, 5 mM EDTA, 1 mM DTT pH 7.5) using a Teflon pestle (Glass-Col, USA) at 900 rpm as described previously by Saxena et al. (2015).<sup>11</sup> The homogenates were centrifuged at 9,000 ×g in a refrigerated centrifuge (4°C) for 10 minutes to remove nuclei and debris. The supernatant obtained was used for biochemical assays and FT-IR analysis. Protein concentration was estimated by the method of Lowry (1951), using bovine serum albumin as the standard.<sup>12</sup>

### Estimation of MDA Levels

The levels of MDA equivalents were determined in tissue samples by TBARS assay kit (Cayman, MI, USA) as describe by Hardwick et al. 2010.<sup>13</sup> The absorbance was determined spectrophotometrically at a wavelength of 540 nm using a spectrophotometer.

### Assessment of Antioxidant Enzymatic Activities

Glutathione peroxidase (GPx) activity was measured using an assay kit (Cayman, MI, USA). The experimental procedures were carried out according to the manufacturer's instructions.<sup>14</sup> The measurement of GPx activity is based on the principle of a coupled reaction with glutathione reductase (GR). The oxidized glutathione (GSSG) formed after reduction of hydro peroxide by GPx is recycled to its reduced state by GR in the presence of NADPH. The oxidation of NADPH is accompanied by a

decrease in absorbance at 340 nm. One unit of GPx was defined as the amount of enzyme that catalyzes the oxidation of 1 nmol of NADPH per minute at 25°C.

Superoxide dismutase (SOD) activity was determined using an assay kit (Cayman, MI, USA). This kit utilizes a tetrazolium salt for the detection of superoxide radicals generated by xanthine oxidase and hypoxanthine. One unit of SOD was defined as the amount of enzyme needed to produce 50% dismutation of superoxide radical.

### Statistical Analysis

All data was analyzed with the Statistical Package for the Social Sciences (SPSS) 21.0 software. Data are expressed as means ± standard error of means (SEM) for each group of treatment. Statistical analysis using One way Analysis of Variance (ANOVA) was performed to determine the difference of the means of between the treatments at p<0.05.

## RESULTS

### Oxidative Stress Marker and Antioxidant Enzymes

The oxidant and antioxidant status in pancreas was monitored to support the pancreas-protective effect of *A. excelsa*. Table 2 summarizes the results for the effect of *A. excelsa* on pancreas lipid peroxidation and the activities of antioxidant enzymes. There was a significant decrease in the activity of SOD and GPx of DC rats as compared to NC rats, reflecting the depletion of endogenous antioxidant enzymes activities in serum. However, administration of *A. excelsa* to diabetic rats caused significant increase in the SOD and GPx values relative to DC. Surprisingly, DAE indicate the lowest TBARS level eventually compared with NC group. Unbelievably, DMET remarked the highest TBARS level; consequently with reduce in both SOD and GPx values.

### Pancreas weight

The pancreas weight and relative pancreas weight were measured in order to evaluate the treatment-related effects. The pancreas weight was significantly decreased in all diabetic groups as compared to NC group. Thus, it was observed that the mean values of pancreas weight in DAE increased approaching NC weight as compared to other diabetic treated rats. Therefore, relative pancreas weight was significantly decreased in DC rats. These data indicate that STZ administration already caused a significant loss in pancreas physical measurement. Nevertheless, treatment of diabetic rats with Metformin, *A. excelsa* and quercetin does not significantly improve pancreas physicals measurement.

## DISCUSSION

STZ used for the induction of diabetes is known to mediate the destruction of β-cells by establishing redox-cycles resulting in the formation of ROS which constitute the major inducer agents for cell damage and hence diabetes in the rats.<sup>15</sup>



**Table 2:** Oxidative stress marker and antioxidant enzymes of various experimental groups.

Groups	Oxidative stress marker	Antioxidant enzymes	
	TBARS (nmol MDA/mg protein)	GPx (U/mg protein)	SOD (mU/mg protein)
NC	1.33 ± 0.096	22.38 ± 0.300 <sup>d</sup>	10.01 ± 0.390 <sup>b</sup>
DC	2.15 ± 0.147	7.95 ± 0.545 <sup>b</sup>	0.64 ± 0.499 <sup>a</sup>
DMET	2.25 ± 0.128 <sup>a</sup>	3.24 ± 0.240 <sup>a</sup>	1.22 ± 0.204 <sup>a</sup>
DAE	0.28 ± 0.064	18.30 ± 0.187 <sup>c</sup>	7.95 ± 0.600 <sup>ab</sup>

Superscripts <sup>a, b, c, d</sup> in a column differ significantly at  $p < 0.05$ .

**Table 3:** Mean absolute, relative pancreatic weights of various experimental groups.

Groups	Pancreas weight(g)	Relative pancreas weight (%)
NC	4.10 ± 0.058 <sup>b</sup>	0.97 ± 0.101
DC	1.20 ± 0.100 <sup>a</sup>	0.40 ± 0.125 <sup>a</sup>
DMET	1.63 ± 0.186 <sup>ab</sup>	0.64 ± 0.014
DAE	3.27 ± 0.133 <sup>ab</sup>	1.08 ± 0.107 <sup>b</sup>

Superscripts <sup>a, b</sup> in a column differ significantly at  $p < 0.05$

On the other hand, this study concede that *A. excelsa* helps to prevents oxidative stress in diabetic rats through the increased of pancreatic SOD levels. As it well known, the physiological role of an antioxidant is to prevent damage to cellular components arising as a consequence of chemical reactions involving free radicals.<sup>16,17</sup> Besides, diabetes is characterized by hyperglycemia and hyperlipidemia, two biochemical feature associated with inhibition of endothelial nitric oxide synthase (eNOS), leading to diminished NO production, increased formation of reactive oxygen species (ROS) and formation of free radicals, lower efficacy of antioxidant systems, that are important agents in the development of diabetic complication.<sup>16,18</sup> In this study, administration of *A. excelsa* under diabetic conditions induced an improvement in hyperglycemia and in  $\beta$ -cells function and these effects are associated with antioxidative properties of the extract. In that sense, *A. excelsa* extract possess potent activities that help to prevent oxidative stress restoring mass of  $\beta$ -cells and its structure by reducing damage of pancreatic islets in diabetic rats.<sup>19,20</sup> The plant can exert its action by increasing the proliferation or the renewal of the islet  $\beta$ -cells following destruction by STZ.

Interestingly, the major components found in the ethanolic extract of *A. excelsa* were polyunsaturated fatty acids (51.95%) while another 37.41% were saturated fatty acids and about 10.63% was made up of phytol.<sup>20</sup> Phytol is an acyclic diterpene alcohol which is a part of chlorophyll and also a precursor of vitamin E and K1.<sup>21</sup> DM is reported to elevate the synthesis of saturated fatty acids in the tissues and reduce the polyunsaturated fatty acid levels as polyunsaturated fatty acids were more prone to the reactive oxygen species (ROS) attack.<sup>22</sup> It has been proven that a dietary consisting of polyunsaturated fatty acids has significantly lowered the prevalence of steatosis in patients with type II diabetesmellitus.<sup>23</sup> As

this ethanolic plant extract also contained higher polyunsaturated fatty acid levels, it could be a promising treatment for hyperlipidemia and tissue steatosis in type II diabetes mellitus. Thus, this present study suggests that ethanolic extract of *A. excelsa* possesses a great potential to treat diabetes mellitus based on the identified compounds that might work as a synergy and hence, enable this extract to exert an antidiabetic effect.

## CONCLUSION

In conclusion, this study demonstrated that *A. excelsa* promote pancreas cell replenishment by improving the activities of pancreatic antioxidant enzymes. This raises the possibility of using *A. excelsa* and quercetin as a valuable ancillary treatment that could add a novel layer of protection for the  $\beta$ -cell.

**Acknowledgement:** This project was financially supported by Faculty of Applied Science, University Technology MARA.

## REFERENCES

1. Hamann C, Kirschner S, Günther KP, Hofbauer LC, Bone, sweet bone—osteoporotic fractures in diabetes mellitus, *Nature Reviews Endocrinology*, 8(5), 2012, 297-305.
2. Abdalwahed S, Osteoporosis and type 2 diabetes mellitus: what do we know, and what we can do?, *Patient preference and adherence*, 6, 2012, 435-48.
3. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2· 7 million participants, *The Lancet*, 378(9785), 2011, 31-40.

4. Diabetes Malaysia Association (2011). Profile of the diadnosed. In what is diabetes? Retrieved March 20, 2013 from <http://www.diabetes.org.my/articles.phd?aid=5>.
5. Ozougwu JC, Obimba KC, Belonwu CD, Unakalamba CB, The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus, *Journal of Physiology and Pathophysiology*, 4(4), 2013, 46-57.
6. Shukor NA, Seong LK, Azadirachtin Variation of Six Provenances of *Azadirachta excelsa* (Jack) Jacob, Pakistan Journal of Biological Sciences, 9(5), 2006, 833-6.
7. Nurul 'Izzati S, Nurdiana S, Hafandi A, Mohd Zakihalani AH, Norashirene MJ, SitiKhairiyah MH, Antioxidant and Hypoglycemic Activities of *Azadirachta excelsa* in Diabetic Rats, ISBEIA 2013: IEEE Symposium on Business, Engineering and Industrial Applications, Kuching, 2013, 63.
8. Nurdiana S, Nurul'Izzati S, Khairiyah MS, Zulaikha MN, Kamaruddin MS, Norashirene MJ, Repopulation of the Atrophied Uterine in Diabetic Rats by *Azadirachta excelsa* Leaves Extract, IERI Procedia, 5, 2013, 166-71.
9. kiran et al., 2011
10. Al-Mustafa AH, Al-Thunibat OY, Antioxidant activity of some Jordanian medicinal plants used traditionally for treatment of diabetes, *Pak J BiolSci*, 11(3), 2008, 351-8.
11. Saxena AK, Abdul-Majeed SS, Gurtu S, Mohamed WM. Investigation of redox status in chronic cerebral hypo perfusion-induced neurodegeneration in rats. *Applied & translational genomics*, 5, 2015, 30-2.
12. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, Protein measurement with the Folin phenol reagent. *J biolChem*, 193(1), 1951, 265-75.
13. Hardwick RN, Fisher CD, Canet MJ, Lake AD, Cherrington NJ, Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease, *Drug metabolism and disposition*, 38(12), 2010, 2293-301.
14. Eslami H, Batavani RA, Asr S. Changes of stress oxidative enzymes in rat mammary tissue, blood and milk after experimental mastitis induced by *E. coli* lipo polysaccharide. In *Veterinary Research Forum 2015*, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran, 6(2), 2015, 131.
15. Szkudelski T, The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas, *Physiological research*, 50(6), 2001, 537-46.
16. Young IS, Woodside JV, Antioxidants in health and disease, *Journal of clinical pathology*, 54(3), and 2001, 176-186.
17. Juárez-Rojop IE, Díaz-Zagoya JC, Ble-Castillo JL, Miranda-Osorio PH, Castell-Rodríguez AE, Tovilla-Zárate CA, Rodríguez-Hernández A, Aguilar-Mariscal H, Ramón-Frías T, Bermúdez-Ocaña DY, Hypoglycemic effect of *Carica papaya* leaves in streptozotocin-induced diabetic rats, *BMC Complementary and Alternative Medicine*, 12(1), 2012, 236.
18. Sheweita SA, Mashaly S, Newairy AA, Abdou HM, Eweda SM, Changes in oxidative stress and antioxidant enzyme activities in streptozotocin-induced diabetes mellitus in rats: Role of *Alhagi maurorum* extracts, *Oxidative medicine and cellular longevity*, 2016 Jan 18;2016.
19. Ding Y, Zhang Z, Dai X, Jiang Y, Bao L, Li Y, Li Y, Grape seed proanthocyanidins ameliorate pancreatic beta-cell dysfunction and death in low-dose streptozotocin-and high-carbohydrate/high-fat diet-induced diabetic rats partially by regulating endoplasmic reticulum stress, *Nutrition & metabolism*, 10(1), 2013, 51.
20. Shafie NI, Samsulrizal N, Sopian NA, Rajion MA, Meng GY, Ajat MM, Ahmad H, Qualitative phytochemical screening and GC-MS profiling of *Azadirachta excelsa* leaf extract, *Malaysian Applied Biology*, 44(3): 2015, 87-92.
21. Sermakkani M, Thangapandian V, GC-MS analysis of *Cassia italica* leaf methanol extract, *Asian journal of pharmaceutical and clinical research*, 5(2), 2012, 90-4.
22. Saravanan G, Ponnuragan P, Antidiabetic effect of S-allylcysteine: effect on thyroid hormone and circulatory antioxidant system in experimental diabetic rats, *Journal of Diabetes and its Complications*, 26(4), 2012, 280-5.
23. Petit JM, Guieu B, Duvillard L, Jooste V, Brindisi MC, Athias A, Bouillet B, Habchi M, Cottet V, Gambert P, Hillon P, Increased erythrocytes n-3 and n-6 polyunsaturated fatty acids is significantly associated with a lower prevalence of steatosis in patients with type 2 diabetes, *Clinical Nutrition*, 31(4), 2012, 520-5.

**Source of Support: Nil, Conflict of Interest: None.**